Vitamin A Status in Patients With Vocal Fold Leukoplakia
Launched by UNIVERSITY OF WISCONSIN, MADISON · Apr 11, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The investigator's overarching goal is to determine if there is a pathophysiologic rationale for vitamin A supplementation in the treatment of vocal fold hyperkeratosis. Vocal fold hyperkeratosis is an accumulation of epithelial surface keratin resulting in clinical leukoplakia. It is primarily managed using destructive techniques that risk iatrogenic injury, fibrosis, and voice impairment. Given the potential morbidity of biopsy and lesion removal, there is a need for new approaches to the prevention and treatment of vocal fold leukoplakic disorders that are non-destructive. Vitamin A is a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Willing to provide informed consent.
- • 2. Willing to comply with all study procedures and be available for the duration of the study.
- • 3. Ability to take oral medication.
- • 4. At least 18 years of age.
- 5. Leukoplakia study groups:
- • 1. Leukoplakia due to hyperkeratosis with dysplasia: biopsy-confirmed diagnosis of hyperkeratosis with dysplasia.
- • 2. Leukoplakia due to hyperkeratosis with no dysplasia: biopsy-confirmed diagnosis of hyperkeratosis with no dysplasia.
- • 6. Control group: Laryngoscopy showing no evidence of vocal fold epithelial disease.
- Exclusion Criteria:
- • 1. History of malignant vocal fold epithelial pathology.
- • 2. History of metabolic or liver disorder.
- • 3. History of anorexia or bulimia.
- • 4. Pregnant, lactating, or planning on becoming pregnant during the study period.
- • 5. History of \>4.5 kg weight loss in the past 90 days.
- • 6. Medical or other inability to complete an 8 hour fast.
- • 7. Acute respiratory or gastrointestinal illness.
- • 8. Currently incarcerated.
- • 9. Impaired decision-making capacity.
- • 10. No or limited English speaking ability; illiterate or low-literacy ability.
- • 11. Profound visual or hearing impairment that limits written or verbal communication.
- • 12. Status relationship with a member of the study team.
- • 13. Not suitable for study participation due to other reasons at the discretion of the investigators.
About University Of Wisconsin, Madison
The University of Wisconsin-Madison is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources, including cutting-edge facilities and a diverse pool of expert researchers, to conduct rigorous studies that address critical health challenges. The institution's focus on translating research findings into practical applications fosters the development of new treatments and interventions, ultimately contributing to improved patient outcomes and public health initiatives. As a sponsor of clinical trials, the University of Wisconsin-Madison is dedicated to upholding the highest ethical standards and ensuring participant safety throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madison, Wisconsin, United States
Patients applied
Trial Officials
Nathan Welham, PhD, CCC-SLP
Principal Investigator
University of Wisconsin, Madison
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials